Engflag

Konsyl

Quick links to important sections

Konsyl

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Konsyl

Property Description
Active ingredient Psyllium Hydrophilic Mucilloid (Ispaghula)
Form Powder, Granules, Capsules (for oral suspension)
Pharmacological class Bulk-forming laxative
Common use Promoting bowel regularity, managing fiber deficiency
Origin Natural (seed husks of the Plantago ovata plant)

Defining Konsyl: Active Ingredient and Pharmacological Class

Konsyl is defined as an over-the-counter (OTC) medicine classified as a bulk-forming laxative and a reliable source of dietary fiber. Its core identity comes from its single active compound, Psyllium Hydrophilic Mucilloid, which is pharmaceutically interchangeable with Ispaghula. This bulk-forming ingredient is used to assist in restoring regularity.

The compound is of natural origin, derived from the highly purified seed husks of the Plantago ovata plant. The non-stimulant nature supports its general use in promoting sustained and predictable bowel regularity, distinguishing its mechanical action from that of chemical stimulant laxatives. This gentle action makes it a primary focus for patients seeking long-term digestive support.

Composition, Forms, and Differentiation

The active substance in Konsyl is Psyllium Hydrophilic Mucilloid, a potent form of non-fermentable hemicellulose that remains unabsorbed by the body. This single-ingredient product is engineered for high-purity fiber delivery. As a bulk-forming agent, psyllium works by absorbing liquid in the intestines, swelling, and forming a bulky stool that is easy to pass.

This medicine is administered via the oral route and is widely available in various dosage form(s), including fine powder intended for mixing into liquids, granules, and capsules. Konsyl differentiates itself through specific formulation features, such as low-sodium options, making it a targeted choice for patients on restricted diets who require a bulk-forming agent.

General Purpose and Benefit of Bulk-Forming Fiber

The general purpose of utilizing this product is to restore and maintain bowel regularity and assist in managing a fiber deficiency. This benefit is typically sought in scenarios of occasional irregularity or when dietary intake of fiber is insufficient.

Upon ingestion, the Psyllium Hydrophilic Mucilloid rapidly forms a viscous gel, which dramatically increases the mass and hydration of the intestinal contents. This increase in bulk facilitates the formation of a soft, substantial fecal mass. The mechanical presence of this larger stool volume then naturally encourages the intestinal muscles to move contents through the bowel. This physical action addresses issues related to irregularity by promoting the comfortable passage of stools, delivering a reliable mechanical benefit without reliance on chemical stimulation.

Regulatory References

  1. Psyllium Husk Label on DailyMed
  2. Psyllium Drug Information (MedlinePlus)
  3. Soluble vs. Insoluble Fiber (MedlinePlus Medical Encyclopedia)

What side effects are possible with Konsyl?

Possible Side Effects and Safety Information

The safety profile for Psyllium Hydrophilic Mucilloid (Ispaghula), the active ingredient in Konsyl, is officially documented by government regulatory authorities and focuses primarily on gastrointestinal effects and systemic hypersensitivity.

Documented Adverse Reactions

The most commonly reported adverse events are linked to the bulk-forming nature of the product and often occur within the Gastrointestinal Disorders system-organ class. These include flatulence and abdominal distension (bloating), which are often noted to be more likely experienced during the first few days of treatment.

In the Immune System Disorders class, the regulatory safety profile includes warnings for hypersensitivity reactions. While the frequency of these systemic reactions is generally classified as Not known (cannot be estimated from the available data), documented events include skin rash, urticaria, bronchospasm, and, rarely, severe reactions like anaphylaxis.

Serious Safety Considerations

Official labels highlight the risk of serious adverse reactions, which are generally related to the physical action of the fiber, particularly if taken without sufficient fluid. These risks include intestinal obstruction, esophageal obstruction, and faecal impaction.

Administration-agnostic safety constraints emphasize that the product is contraindicated in patients with pre-existing conditions such as established intestinal obstruction, colonic atony, faecal impaction, or difficulty swallowing. Furthermore, the bulk-forming action may cause a delay in the enteral absorption of other simultaneously administered oral medications, a high-level safety consequence noted in regulatory texts.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

The regulatory profile for an overdose of Psyllium Hydrophilic Mucilloid primarily addresses the risks associated with the bulking properties of the fiber, particularly when consumed with inadequate fluid. Documented overdose presentations include local gastrointestinal manifestations such as abdominal discomfort and flatulence, alongside the risk of severe complications like intestinal obstruction and esophageal impaction.

The most serious outcomes are the life-threatening risks of choking and difficulty in swallowing or breathing, which are explicitly cited in government warnings as requiring immediate medical intervention. Overdose management is limited to symptomatic and supportive treatment, as regulatory documents do not specify a pharmacological antidote. Population-specific notes indicate that the risk of dehydration and electrolyte imbalance is observed to be more prevalent in children during general laxative overdose scenarios.

When to Seek Urgent Medical Help (Label-Derived Phrasing)

  • Immediate medical attention must be sought if symptoms such as chest pain, vomiting, or any difficulty in swallowing or breathing occur after taking the product.
  • In the event of a suspected or confirmed overdose, the required action is to contact a doctor or a Poison Control Center right away, as stated in official labeling.

Connection to the Overall Overdose Profile

The official overdose profile is defined by the substantial physical obstruction risk associated with the fiber's non-systemic action, particularly when inadequate fluid is consumed. Regulatory guidance strictly links the development of specific, severe symptoms (e.g., choking) to the need for urgent help-seeking. Subsequent management procedures focus on supportive care and monitoring, consistent with a non-antidotal approach described in regulatory resources.

Therapeutic Uses of Konsyl

What Konsyl treats: Main Uses and Benefits

This fiber agent is primarily relevant for easing symptoms that interfere with daily functioning, such as chronic or occasional infrequent defecation, and symptoms related to physical discomfort. This bulk-forming fiber is commonly used to help manage constipation and contributes to easing the overall symptom load by supporting functional stability.

Beyond this primary role, the medication is applied in managing symptoms that create noticeable physiological strain, such as excessive straining during elimination, and is relevant when supportive symptom management is appropriate in conditions like hemorrhoids and anal fissures. Furthermore, the fiber is considered relevant in contexts involving heightened systemic burden, as it supports the management of systemic imbalance related to hypercholesterolemia (elevated LDL cholesterol) and may assist with blood glucose management in patients with Type 2 diabetes. This provides supportive relief that helps patients cope more steadily with symptom fluctuations associated with these long-term conditions.

Quick Fact: Symptomatic Relief for Straining

This product is commonly used to help manage symptoms related to physical discomfort associated with elimination, and is relevant for easing symptoms of excessive straining to support general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Konsyl?

Eligibility for using Konsyl (Psyllium Hydrophilic Mucilloid) is strictly defined by regulatory labeling, centering on patient age, ability to swallow, and pre-existing gastrointestinal conditions.

Approved Age Groups and Status

Age Group Eligibility Status
Adults (12+ years) Approved for standard labeled use.
Children (6–12 years) Approved for use at a labeled dose.
Children Under 6 Not recommended without consulting a health professional.

Absolute Contraindications (Must Not Use)

Use of Konsyl is contraindicated in patients with a known hypersensitivity or allergy to psyllium. It is also forbidden for individuals with difficulty in swallowing, a known or suspected gastrointestinal obstruction, or fecal impaction. Use is restricted and requires immediate consultation if a patient experiences acute symptoms like abdominal pain, nausea, vomiting, or difficulty breathing.

Pregnancy and Lactation Eligibility

Pregnant individuals must ask a health professional before use. The product is generally considered acceptable during breastfeeding as the active ingredient is not absorbed systemically and cannot pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Konsyl (Psyllium Hydrophilic Mucilloid) interacts with other orally administered medicines primarily through a physical mechanism that may reduce or delay their absorption in the gastrointestinal tract. This can potentially lower the overall exposure and effectiveness of the co-administered drug.

Required Timing Separation

To mitigate the risk of reduced absorption, official regulatory guidance stipulates a time separation for intake. The product should generally not be taken within one hour before or after other oral medicinal products. US-based information often recommends separating intake by at least two hours.

Documented Exposure-Altering Interactions

Due to the bulk-forming fiber's interference with absorption, regulatory information specifically notes a potential reduction in the bioavailability of several substances:

  • Cardiac Glycosides: Such as digoxin.
  • Anticoagulants: Including warfarin and related coumarin derivatives.
  • Anticonvulsants: Such as carbamazepine and lithium.
  • Essential Nutrients: Including Vitamin B12 and minerals like calcium, iron, and zinc.

High-Risk Combination and Special Cautions

  • Peristalsis-Inhibiting Agents: Konsyl should not be used together with medicinal products known to inhibit peristaltic movement (e.g., opioids), as this combination significantly increases the risk of intestinal obstruction.
  • Hormonal/Metabolic Agents: Patients taking anti-diabetic agents or thyroid hormones require medical supervision, as a dose adjustment of these therapies may be necessary due to the fiber's potential systemic effect.

Mechanism of Action

How Konsyl Works

The action of Psyllium Hydrophilic Mucilloid, the active ingredient in Konsyl, is physicomechanical, influencing the gastrointestinal tract without engaging systemic drug receptors or enzymes. Its effect is achieved through three interconnected mechanisms in the intestinal lumen.

Modulation of Luminal Fluid Dynamics and Stool Hydration

This mechanism begins with the high-capacity hydrophilic binding of water in the small intestine and colon. Upon contact with fluid, the fiber transforms into a large, highly viscous gel, which is its primary mechanical target. This process ensures the fecal contents are significantly bulkier, which reduces the rate of water reabsorption, contributing to a cohesive and softened mass.

Mechanical Activation of Intestinal Motility

The physically distending effect of the hydrated mucilage against the intestinal wall activates the mechanoreceptors embedded in the colonic smooth muscle. This activation of the gut's intrinsic neural network (myenteric plexus) increases the rate and force of propulsive peristaltic contractions. This heightened muscle activity, driven by the physical bulk, determines the final rate of propulsive transit.

Colonic Microenvironment and SCFA Production

A smaller fraction of the Psyllium fiber undergoes partial fermentation by resident colonic bacteria. This interaction is metabolic, yielding short-chain fatty acids (SCFAs) like butyrate as localized byproducts. This secondary mechanism modulates the colonic microenvironment and is an ancillary biological interaction to the bulking and motility-modulating actions.

Dosage and Administration Information

How to Use Konsyl (Psyllium Hydrophilic Mucilloid)

Instructions for the administration and dosing of psyllium hydrophilic mucilloid, the active ingredient in Konsyl, include specific preparation, timing, and dosage based on age to ensure correct use.

Route and Preparation

Instruction Entity Instruction Detail
Route of administration Oral (by mouth).
Preparation requirements Must be mixed with a full glass (at least 8 ounces) of water or other fluid.
Special conditions Stir briskly and drink promptly. Follow with an additional glass of liquid.

Standard Dosing and Timing

Age Group Standard Dose per Administration
Adults and Children 12 years and older 1 teaspoon or 1 rounded tablespoon.
Children 6 to under 12 years 1/2 the adult dose.

Frequency is typically 1 to 3 times per day. New users are directed to start with one dose daily and gradually increase as needed. Children under 6 years of age should only be administered this product after consulting a healthcare professional.

Procedural Constraints

Two critical constraints must be observed. First, if taking a prescribed oral medication, take this product at least 2 hours before or 2 hours after the prescribed medicine to prevent absorption interference. Second, the product is not intended for long-term use; do not take for a period longer than 7 days unless directed to do so by a doctor. These procedural steps are mandatory components of the use protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Konsyl

The research evidence available for the active ingredient in Konsyl, Psyllium Hydrophilic Mucilloid, comes from formal studies, including clinical trials and published scientific reviews. Research examines how the medicine was observed in and the outcomes related to bowel function and certain metabolic factors. Findings describe group patterns observed in the studies, which provide context but not individual predictions.

Evidence for Use in Promoting Bowel Regularity

Research has examined the use of psyllium in individuals experiencing chronic or occasional infrequent bowel movements. Short-term clinical trials were conducted, comparing psyllium against placebos or a low-fiber control. Primary measurements included frequency of bowel movements and patient-reported outcomes related to the effort required for defecation (straining). Findings describe patterns observed in the studies where measurements indicated shifts toward more frequent and softer stools. There is limited information for long-term outcomes, and evidence quality varies across studies.

Evidence for Metabolic Support in Cholesterol and Blood Glucose Management

Research also was studied for its use in two areas related to metabolic markers: managing elevated cholesterol and researching changes in blood glucose management in Type 2 diabetes. Studies monitored changes in biomarkers, primarily Low-Density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol. Research highlights changes measured during the study period, where findings described lower measurements of these markers. For individuals with T2DM, studies monitored changes in markers like Glycated Hemoglobin A1c (HbA1c) and Fasting Blood Glucose (FBG).

What Remains Uncertain About Psyllium Research

The majority of evidence was primarily studied in healthy or generally stable adult populations. Comparative evidence is lacking for many head-to-head comparisons against prescription treatments. Subgroup findings are uncertain for many specific populations, and there is limited information for long-term outcomes and the sustained nature of the observed changes across all indications.

How should Konsyl be stored and disposed of?

How to Store and Dispose of Konsyl?

The official labeling for this psyllium husk product specifies strict requirements for storage and disposal to maintain stability and integrity.

Storage Conditions

Requirement Specific Condition
Temperature Store at controlled room temperature, 68 F to 77 F (20 C to 25 C), with a maximum limit of 86 F (30 C).
Protection Keep container tightly closed to protect from excessive moisture.
Container Integrity Do not use if the imprinted inner seal is missing or broken.
Child Safety Keep out of reach of children.

Disposal Requirements

Due to the highly absorbent nature of the bulk-forming fiber, regulatory documents mandate that users do not discard Konsyl into any plumbing system (e.g., sink or toilet). Unused or expired product should be managed according to general guidelines for non-hazardous household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Konsyl found in:

A-Z Index: